Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS)
David Price (Aberdeen, United Kingdom), David Price, Daniela Van Eickels, Matthias Binek, Mona Khalid, Ron M.C. Herings, Jetty Overbeek, Richard Dekhuijzen, Thys Van der Molen, Wim Van Aalderen, Gene Colice, Theresa Guilbert, Eliot Israel, Richard Martin, Dirkje Postma, Nicolas Roche, Vicky Thomas, Cristiana Miglio
Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
David Price (Aberdeen, United Kingdom), David Price, Daniela Van Eickels, Matthias Binek, Mona Khalid, Ron M.C. Herings, Jetty Overbeek, Richard Dekhuijzen, Thys Van der Molen, Wim Van Aalderen, Gene Colice, Theresa Guilbert, Eliot Israel, Richard Martin, Dirkje Postma, Nicolas Roche, Vicky Thomas, Cristiana Miglio. Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS). Eur Respir J 2015; 46: Suppl. 59, 3259
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Add-on effects of long-acting beta2 -agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011